The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress
Lung diseases are the leading cause of mortality worldwide. The currently available
therapies are not sufficient, leading to the urgent need for new therapies with sustained anti …
therapies are not sufficient, leading to the urgent need for new therapies with sustained anti …
[HTML][HTML] Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome
M Zoulikha, Q **ao, GF Boafo, MA Sallam… - … Pharmaceutica Sinica B, 2022 - Elsevier
The use of small interfering RNAs (siRNAs) has been under investigation for the treatment of
several unmet medical needs, including acute lung injury/acute respiratory distress …
several unmet medical needs, including acute lung injury/acute respiratory distress …
Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge
Interleukin-11 (IL-11) is a profibrotic cytokine essential for the differentiation of fibroblasts
into collagen-secreting, actin alpha 2, smooth muscle–positive (ACTA2+) myofibroblasts …
into collagen-secreting, actin alpha 2, smooth muscle–positive (ACTA2+) myofibroblasts …
siRNA versus miRNA as therapeutics for gene silencing
Discovered a little over two decades ago, small interfering RNAs (siRNAs) and microRNAs
(miRNAs) are noncoding RNAs with important roles in gene regulation. They have recently …
(miRNAs) are noncoding RNAs with important roles in gene regulation. They have recently …
[HTML][HTML] Pulmonary delivery of biological drugs
In the last decade, biological drugs have rapidly proliferated and have now become an
important therapeutic modality. This is because of their high potency, high specificity and …
important therapeutic modality. This is because of their high potency, high specificity and …
Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation
Background First vaccines for prevention of Coronavirus disease 2019 (COVID‐19) are
becoming available but there is a huge and unmet need for specific forms of treatment. In …
becoming available but there is a huge and unmet need for specific forms of treatment. In …
[HTML][HTML] Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
C Lorenzer, M Dirin, AM Winkler, V Baumann… - Journal of Controlled …, 2015 - Elsevier
Therapeutic gene silencing promises significant progress in pharmacotherapy, including
considerable expansion of the druggable target space and the possibility for treating orphan …
considerable expansion of the druggable target space and the possibility for treating orphan …
A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers
RM Rasul, MT Muniandy, Z Zakaria, K Shah… - Carbohydrate …, 2020 - Elsevier
Chitosan, as a biodegradable and biocompatible polymer, is characterized by anti-microbial
and anti-cancer properties. It lately has received a widespread interest for use as the …
and anti-cancer properties. It lately has received a widespread interest for use as the …
Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview
Drugs are introduced into the body by numerous routes such as enteral (oral, sublingual and
rectum administration), parenteral (intravascular, intramuscular, subcutaneous and …
rectum administration), parenteral (intravascular, intramuscular, subcutaneous and …
Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery
H Wang, L Qin, X Zhang, J Guan, S Mao - Journal of Controlled Release, 2022 - Elsevier
With the rapid development of biopharmaceuticals and the outbreak of COVID-19, the world
has ushered in a frenzy to develop gene therapy. Therefore, therapeutic genes have …
has ushered in a frenzy to develop gene therapy. Therefore, therapeutic genes have …